Journal of Obesity and Metabolism
Open Access

Adolescent; Cardiometabolic risk; Diet Quality; Food knowledge; Obesity; Psychosocial wellbeing; Extreme corpulence; Stress

Introduction

Mucopolysaccharidoses (MPSs) are a gathering of intriguing acquired lysosomal capacity problems brought about by a lack of fundamental proteins for the corruption of glycosaminoglycans (GAGs). The amassing of GAGs makes harm different organs, including the heart [1]. Mitral and aortic valve diseases (regurgitation and/or stenosis) and the prevalence of aortic stenosis (AS) are the most common cardiac manifestations. While severe AS has been treated with surgical aortic valve replacement (SAVR) in MPS, multisystem disorders frequently render patients inoperable [2]. However, the medium- and longterm outcomes of transcatheter aortic valve replacement (TAVR) are unknown, and there are few reports of the procedure. Due to her high risk for SAVR, our young patient with MPS type I-HS (Hurler-Scheie syndrome) underwent TAVR for severe AS and has demonstrated a straightforward medium-term outcome.

Deficits in lysosomal enzymes and the accumulation of glycosaminoglycans in various organs, including the heart, are hallmarks of mucopolysaccharidoses (MPSs), an inherited metabolic disorder [3]. Aortic valve disease, in particular, is associated with high rates of morbidity and mortality and occasionally necessitates early surgical aortic valve replacement (SAVR). Although transcatheter aortic valve replacement (TAVR) is a well-established treatment for severe aortic stenosis (AS) in surgically high-risk patients, there are few reports of TAVR in MPS, and neither the medium-term nor the longterm outcomes are known. An MPS patient at high risk for SAVR who was successfully treated with TAVR and has demonstrated a satisfactory medium-term outcome is the subject of our case study of severe AS. A 40-year-old woman with MPS type I-HS (Hurler-Scheie syndrome) who was receiving enzyme replacement therapy as a systemic treatment for syncope and worsening dyspnea was found to have severe AS [4]. Due to the difficulty of endotracheal intubation, the patient had previously undergone a temporary tracheotomy. Taking into account the gamble for general sedation, TAVR was performed under nearby sedation. For the past one and a half years, her symptoms have decreased. TAVR for serious AS in MPS would be an elective choice for careful highrisk patients and can exhibit ideal medium-term results joined with fundamental treatments.

Hearing loss, developmental delays, hepato-splenomegaly, macroglossia, obstructive sleep apnea, heart disease, recurrent respiratory infections, progressive corneal clouding blindness, and skeletal and facial deformities are all features of Hurler syndrome, an autosomal recessive hereditary disorder [5]. It is caused by a lack of the lysosomal enzyme alpha-L-Iduronidase, which is needed to hydrolyze mucopolysaccharides, particularly two glycosaminoglycans (GAG): heparan sulfate and dermatan sulfate. The glycosaminoglycans (heparan and dermatan sulfate) are then stored in lysosomes within the cell. This prompts moderate disturbance of the intracellular and extracellular climate and the brokenness of different organ frameworks. Storage cells, Hurler cells, and gargoyle cells are the various names given to the affected cells.

This study reaches out earlier cross-sectional work by examining how this equivalent accomplice of patients has worked over the long haul and whether their life change has been impacted. A group of non- L238Q Hurler-Scheie patients serves as a comparison group for these longitudinal findings. It was quite compelling to see if these patients showed a decrease in working over the long haul [6]. This analysis tested the primary hypothesis that, although Hurler-Scheie syndrome patients’ medical symptoms would likely get worse over time, their neurocognitive and neuropsychiatric status would remain stable and within the normal range.

A combination of bioinformatics tools and a 3D structural analysis were also used to better comprehend the effects that L238Q has on the IDUA enzyme.

Mitral and aortic valve diseases (regurgitation and/or stenosis) are the most common cardiac manifestations; the prevalence of aortic stenosis (AS) ranges from 3 to 36%. While severe AS has been treated with surgical aortic valve replacement (SAVR) in MPS, multisystem disorders frequently render patients inoperable [7]. However, the medium- and long-term outcomes of transcatheter aortic valve replacement (TAVR) are unknown, and there are few reports of the procedure. Due to her high risk for SAVR, our young patient with MPS type I-HS (Hurler-Scheie syndrome) underwent TAVR for severe AS and has demonstrated a straightforward medium-term outcome.

Materials and Method

One year prior to admission, a large left nasal polyp of inflammatory origin was removed. There was also a history of frequent otitis media [8]. No further past history and family history were available.

He had pathognomonic facial features of Hurler’s syndrome, including a large nose, depressed nasal bridge, large lips, low-set ears, hyperplastic gingiva, large tongue, and frontal bossing [9]. There was corneal opacification bilaterally. The abdomen was distended with marked hepato-splenomegaly. The spleen was palpated 3 cm below the costal margin and the liver 5 cm below the costal margin. General lymphadenopathy was noted.

Histopathology of the transient bones

1 hour and 40 minutes have passed since the death and the autopsy. The standard methods of fixation in formalin, decalcification, dehydration, and embedment in celloidin were used to harvest and prepare the two temporal bones [10]. For the purpose of light microscopy, the bones were sectioned horizontally at a thickness of 25 millimeters, and each tenth section was stained with hematoxylin and eosin and mounted on glass slides.

Both fleeting bones are accessible for histopathological assessment from the Albert Einstein School of Medication transient bone research center. The bones are in a superb condition of safeguarding and arrangement with not very many relics. The discoveries are indistinguishable and balanced for both fleeting bones and will be depicted together.

Administration of intrathecal enzyme replacement

T ERT was managed by standard lumbar cut utilizing a sterile method [11]. In 4 mL of Elliott’s B solution, recombinant iduronidase (0.05 mg/kg) was administered over the course of one to two minutes at each time point. Regarding HCT, the infusion of IT ERT was planned for four distinct times: 8-12 weeks before HCT, 2 weeks before HCT, 100 days after HCT, and a half year after HCT. The timing matched with planned sedation. The MPS I canine model’s experience dictated a three-monthly dose. For both pre-HCT time points, IT ERT was administered prior to beginning the transplant preparation regimen. Prior to the first IT ERT dose, patients in two instances received intravenous ERT.

Neurocognitive evaluation

A standard neurocognitive evaluation protocol previously described18 was used for all patients at baseline (before any intervention, except for two patients who had received prior intravenous ERT) and after HCT at annual visits to the University of Minnesota [12]. The neurocognitive evaluations included a test of developing intellectual function: the Mullen Scales of Early Learning28 or the Bayley Scales of Infant and Toddler Development, Third Edition. Both of these tests yield a norm-referenced score that reflects overall neurocognitive functioning (emerging IQ).

The outer ear and center ear

In the middle and external ears, a number of structures have undergone significant pathologic change. Storage cells, or “Hurler cells,” macrophage/histiocyte infiltrates, persistent or unresolved immature mesenchyme, and effusions and edema are the primary pathologic findings [13]. The cells of the macrophage/histiocyte lineage that make up storage cells are filled with mucopolysaccharide material (MPS), which gives the cytoplasm a clear or foamy appearance. Macrophages are essential for ordinary irritation, wherein they phagocytose cell trash from various pathologic cycles; be that as it may, in Thrower’s sickness, they are boundless and relentless, attributable to the powerlessness to appropriately use and clear glycosaminoglycan particles.

The middle ear cleft and mastoid cells are completely filled with a proliferation of stellate cells with delicate cytoplasmic processes, an acellular myxoid matrix, and a rich capillary network, most consistent with unresolved primitive mesenchyme. As a result, there is no aeration in the middle ear spaces. This kind of tissue is normal for the development of the fetus and usually disappears shortly after birth. The mesenchyme covers the malleus’s head and the incus’s body in the superior and posterior mesotympanums.

The MPS accumulation can be seen in the large, clear, vacuolated cytoplasm of the storage cells scattered throughout the middle ear’s large effusion of pink, proteinaceous fluid. The capacity cells are found inside the liquid piece of the emission, in nearby delicate tissue bunches, in the center ear mucosa, and inside the unsettled mesenchyme [14]. Capacity cells are found inside the incudomalleal joint and the versatile filaments of the annular tendon of the stapes bone. Otherwise, the ossicles are normal and there is no damage to the bone. An invasion of capacity cells is distinguished between the profound layers of the skin of the most average part of the outer hearable waterway, inside the annulus, and the tympanic film. In the Eustachian tube region, the ciliated epithelium remains, but it disappears unevenly in other parts of the middle ear. Except for the posterior mastoid region, there is very little hematopoietic activity in the marrow spaces. An infiltrate of storage cells thickens the intimal layer of the carotid artery, significantly constricting the lumen [15]. No calcification is available. Normal are the adventitia, Elastica, and media tunica.

Conclusion

We describe a case of Hurler Syndrome MPS 1-H with both temporal bone histopathology and clinical manifestations. We offer insights into the histopathologic correlates of hearing loss and provide an evaluation of the pathology of the temporal bone. We have demonstrated the presence of embryonic mesenchyme, middle ear fluid, and mucosal inflammation in the spaces around the middle ear, including the include-malleal joints and annular ligaments.

The internal ear structures seemed flawless with typical cell counts and the shortfall of capacity cells all through. In our case of MPS 1-H, we have found no evidence for clinical sensorineural hearing loss or inner ear end-organ temporal bones anomalies.

From our efficient audit, there is proof that the ever-evolving pathologic metabolic course of the illness might influence the inward ear capability at later phases of the infection. It is necessary to clarify the pathophysiology of storage cells and their impact on inner ear function through additional research.

Intrathecal ERT was protected and, in mix with standard treatment, was related with decreases in CSF irregularities. Critically, we demonstrate a connection between Hurler syndrome neurocognitive outcome and a biomarker treatment response.

Acknowledgement

None

Conflict of Interest

None

1. Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, et al. (2020) Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells 9: 1838.

Indexed at, Google Scholar, Crossref

2. Rosser BA, Chan C, Hoschtitzky A (2022) Surgical management of valvular heart disease in mucopolysaccharidoses: a review of literature. Biomedicines 10: 375.

Indexed at, Google Scholar, Crossref

3. Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, et al. (2013) Anaesthesia and airway management in mucopolysaccharidosis. J Inherit Metab Dis 36: 211-219.

Indexed at, Google Scholar, Crossref

4. Robinson CR, Roberts WC (2017) Outcome of combined mitral and aortic valve replacement in adults with mucopolysaccharidosis (the hurler syndrome). Am J Cardiol 120: 2113-2118.

Indexed at, Google Scholar, Crossref

5. Dostalova G, Hlubocka Z, Lindner J, Hulkova H, Poupetova H, et al. (2018) Magner.Late diagnosis of mucopolysaccharidosis type IVB and successful aortic valve replacement in a 60-year-old female patient. Cardiovasc Pathol 35: 52-56.

Indexed at, Google Scholar, Crossref

6. Gabrielli O, Clarke LA, Bruni S, Coppa GV (2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 125: e183-e187.

Indexed at, Google Scholar, Crossref

7. Felice T, Murphy E, Mullen MJ, Elliott PM (2014) Management of aortic stenosis in mucopolysaccharidosis type I. Int J Cardiol 172: e430-e431.

Indexed at, Google Scholar, Crossref

8. Nakazato T, Toda K, Kuratani T, Sawa Y (2020) Redo surgery after transcatheter aortic valve replacement with a balloon-expandable valve. JTCVS Tech 3: 72-74.

Indexed at, Google Scholar, Crossref

9. Gorla R, Rubbio AP, Oliva OA, Garatti A, Marco FD, et al. (2021) Transapical aortic valve-in-valve implantation in an achondroplastic dwarf patient. J Cardiovasc Med (Hagerstown) 22: e8-e10.

Indexed at, Google Scholar, Crossref

10. Mori N, Kitahara H, Muramatsu T, Matsuura K, Nakayama T, et al. (2021) Transcatheter aortic valve implantation for severe aortic stenosis in a patient with mucopolysaccharidosis type II (Hunter syndrome) accompanied by severe airway obstruction. J Cardiol Cases 25: 49-51.

Indexed at, Google Scholar, Crossref

11. Suzuki K, Sakai H, Takahashi K (2018) Perioperative airway management for aortic valve replacement in an adult with mucopolysaccharidosis type II (Hunter syndrome). JA Clin Rep 4: 24.

Indexed at, Google Scholar, Crossref

12. Bevis N, Sackmann B, Effertz T, Lauxmann L, Beutner D, et al. (2022) The impact of tympanic membrane perforations on middle ear transfer function. Eur Arch Otorhinolaryngol 279: 3399-3406.

Indexed at, Google Scholar, Crossref

13. Murgasova L, Jurovcik M, Jesina P, Malinova V, Bloomfield M, et al. (2020) Otolaryngological manifestations in 61 patients with mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol 135: 110-137.

Indexed at, Google Scholar, Crossref

14. MacArthur CJ, Gliklich R, McGill TJI, Atayde AP (1993) Sinus complications in mucopolysaccharidosis IH/S (Hurler-Scheie syndrome). Int J Pediatr Otorhinolaryngol 26: 79-87.

Indexed at, Google Scholar, Crossref

15. Lee CL, Lee KS, Chuang CK, Su CH, Chiu HC, et al. (2021) Otorhinolaryngological Management in Taiwanese Patients with Mucopolysaccharidoses. Int J Med Sci 18: 3373-3379.

Indexed at, Google Scholar, Crossref